Skip to main content

University of Exeter Medical School

Dr Kinan Mokbel

Dr Kinan Mokbel

Academic Lecturer in Clinical Pharmacy & Postdoctoral Research Fellow (E&R)

 K.A.Mokbel@exeter.ac.uk

 Smeall building 

 

Smeall Building, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK


Overview

Kinan Mokbel is a pharmacist who provided healthcare services and contributed to research for 17 years. As an educator, he has taught academic modules to undergraduates, postgraduates, and registered community pharmacists. Kinan is the lead for the following modules in both the MSc Clinical Pharmacy and MSc Advanced Clinical Practice programmes:

 

Kinan is also a Postdoctoral Research Fellow in the Department of Health and Community Sciences as part of the Spotting Cancer among Comorbidities (SPOCC) programme team. Within the SPOCC programme, Kinan conducts research on patient help-seeking behaviours and/or how GPs/nurses identify potential symptoms of cancer. This NIHR-funded initiative, led by the APEx Team at the University of Exeter in collaboration with University College London, aims to understand how pre-existing medical conditions increase the risk of a delayed cancer diagnosis. The ultimate goal is to leverage this information to enhance cancer diagnosis and improve survival rates.

Kinan holds an honorary senior research fellowship at the London Breast Institute in the Princess Grace Hospital, London, since 2016. In this role, he collaborates with a multidisciplinary team on research related to the influence of genetics on treatment response and the development of new breast cancer drugs.


Qualifications

  • Master of Pharmacy
  • Post-graduate Certificate in Pharmacy Education Development
  • Master of Science in Clinical Pharmacy
  • Master of Science in Genomic Medicine
  • PhD - Pharmacogenomics of Medically Important Adverse Drug Effects
  • ASPIRE Higher Education Academy Associate Fellowship
  • Fellow of the Higher Education Academy (FHEA)

Research projects


Research group links


Research interests

  • Spotting cancer among comorbidities and supporting clinical decision-making in patients with symptoms of cancer and pre-existing conditions.
  • Safety of medicines in general practice.
  • The role of community pharmacists in addressing adverse drug effects.
  • Genomic profiling scores for chemotherapy recommendations in women with breast cancer.
  • Prognostication tools in the context of adjuvant treatment of early breast cancer.
  • Genetic testing in clinical practice.
  • Chemoprevention of breast and prostate cancers with vitamins and micronutrients.

Conferences

The Clinical Pharmacy Congress 10-11 May 2024, London, England. The Impact of the COVID-19 Pandemic on Medication Prescribing Patterns in General Practice: A Retrospective Time-trend Analysis. Abstract.

The Clinical Pharmacy Congress North 3-4 November 2023, Manchester, England. A Nationwide Comparative Safety Study of Medicines Within the Therapeutic Class: A Novel Data Integration Approach Based on the Yellow Card Reporting Scheme and the English General Practice Prescription DataAbstract.

The 7th International Congress of the European Society for Pharmacogenomics and Personalised Therapy (ESPT), October 25-27th, 2023, Copenhagen, Denmark. Pharmacogenomic Variants of Medically Important Adverse Effects Related to High-Risk Medicines in General Practice Can Not Be Replicated in UK BiobankAbstract.

The 16th Annual Meeting of Korean Society of Medical Oncology & 2023 International Conference & 11th International FACO Conference, September 7th to 8th 2023, Seoul, Korea. Pharmacogenetics of Endocrine Therapy Associated Toxicities in Breast CancerAuthor URL.

The European Society of Human Genetics Conference, June 10–13th, 2023, Glasgow, Scotland, UK. The Majority of Pharmacogenomic Variants Associated with Adverse Drug Events When Taking Endocrine Therapies for Breast Cancer Can Not Be Replicated in UK Biobank ParticipantsAuthor URL.

The Association for Cancer Surgery Annual Scientific Conference and the NCRI Cancer Conference 5th–8th November 2017 Liverpool, UK. A comparison of the performance of EndoPredict Clinical and NHS PREDICT in 120 patients treated for ER+ breast cancerAuthor URL.


Key Publications

A Comparative Safety Analysis of Medicines Based on the UK Pharmacovigilance and General Practice Prescribing Data in England. URL. PDF.

The Role of Community Pharmacists in Addressing Medication-related Issues for Breast Cancer Patients Receiving Adjuvant Endocrine Therapy. URL. PDF.

Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature. URLPDF.

A Comparison of the Performance of EndoPredict Clinical and NHS PREDICT in 120 Patients Treated for ER-positive Breast Cancer. URL. PDF.

Are online prediction tools a valid alternative to genomic profiling in the context of systemic treatment of ER-positive breast cancer? URLPDF.

The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER+/HER2- Breast Cancer Stratified as Having Moderate or Poor Prognosis by Nottingham Prognostic Index. URL. PDF.

Omitting Sentinel Lymph Node Biopsy After Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis. URLPDF.

Reevaluating Axillary Lymph Node Dissection in Total Mastectomy for Low Axillary Burden Breast Cancer: Insights from a Meta-Analysis including the SINODAR-ONE Trial. URLPDF.

Evaluating Magnetic Seed Localisation in Targeted Axillary Dissection in Patients Undergoing Neoadjuvant Systemic Therapy for Node-Positive Early Breast Cancer: A Systematic Review and Pooled Analysis (In Press).

Pre-pectoral Immediate Breast Reconstruction Following Conservative Mastectomy Using Acellular Dermal Matrix and Semi-smooth Implants. URLPDF.

Chemoprevention of Breast Cancer with Vitamins and Micronutrients: A Concise Review. URL. PDF.

Chemoprevention of Prostate Cancer by Natural Agents: Evidence from Molecular and Epidemiological Studies. URL. PDF.

Does CYP2D6 Genotyping Have a Role in Guiding Tamoxifen Therapy? URL. PDF.

CRISPR/Cas9-Mediated Genome Nano-Surgery: An Update. URL. PDF.

Genetic testing in clinical practice: An ethical perspective. PDF.

The Intrinsic Pathway of Apoptosis and Carcinogenesis: An Update. URL. PDF.

Harnessing Micronutrient Power: Vitamins, Antioxidants, and Probiotics in Breast Cancer Prevention (In Press)

Back to top


Publications

Back to top


Edit Profile